The protein encoded by the c-erbB-2 gene is a membrane receptor expressed in a variety of solid human cancers and directly related to poor prognosis. The objective of this work was to evaluate the clinical value of the quantification of membranous oncoprotein levels in gastric cancer.
Materials and methods
Membranous c-erbB-2 levels were examined by means of a sandwich immunoenzymatic assay in 82 patients with gastric cancer. The median follow-up period for these patients was 16 months. In addition, c-erbB-2 expression was analyzed by immunohistochemistry in 57 gastric carcinomas.
Results
Membranous c-erbB-2 levels ranged widely in the studied tumors (44–112,000 NHU/mg protein). Median c-erbB-2 content was significantly higher in intestinal-type tumors than in diffuse-type tumors (p=0.01). In addition, high levels of c-erbB-2 were significantly associated with shorter relapse-free survival and overall survival in patients with resectable gastric carcinomas (p=0.01 and p=0.04, respectively). However, the correlation between immunohistochemistry and ELISA determinations did not reach statistical significance.
Conclusion
Our results suggest a potential prognostic value of membranous c-erbB-2 quantification by immunoenzymatic assay in gastric cancer. However, its possible role in the selection of patients with a view to the possible introduction of Herceptin as a novel drug against gastric cancer is at present uncertain.
UllrichA., SchlessingerJ.. Signal transduction by receptors with tyrosine kinase activity.Cell1990; 61: 203–12.
2.
Pinkas-KramarskiR., SoussanL., WatermanH.. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.EMBO J1996; 15: 2452–67.
3.
de LangeT.. Activation of telomerase in a human tumor.Proc Natl Acad Sci USA1994; 91: 2882–5.
4.
DrebinJ., LinkV., SternD., WeinbergR., GreeneM.. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.Cell1985; 41: 697–706.
5.
BaselgaJ., TripathyD., MendelsohnJ.. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.J Clin Oncol1996; 14: 737–44.
6.
SlamonD., Leyland-JonesB., ShakS.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med2001; 344: 783–92.
7.
SalomonD., BrandtR., CiardielloF., NormannoN.. Epidermal growth factor-related peptides and their receptors in human malignancies.Crit Rev Oncol Hematol1995; 19: 183–232.
8.
JainS., FilipeM.I., GullickW.J., LinehanJ., MorrisR.W.. c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material.Int J Cancer1991; 48: 668–71.
9.
YonemuraY., NinomiyaI., OhoyamaS.. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma.Cancer1991; 67: 2914–8.
10.
OhguriT., SatoY., KoizumiW., SaigenjiK., KameyaT.. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator?Int J Cancer1993; 53: 75–9.
11.
LeeE.Y., CibullM.L., StrodelW.E., HaleyJ.V.. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.Arch Pathol Lab Med1994; 118: 235–9.
12.
TsugawaK., YonemuraY., HironoY.. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features.Oncology1998; 55: 475–81.
GurelS., DolarE., YerciO.. The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer.J Int Med Res1999; 27: 74–8.
15.
NakajimaM., SawadaH., YamadaY.. The prognostic significance of amplification and overexpression of c- met and c-erb B-2 in human gastric carcinomas.Cancer1999; 85: 1894–902.
16.
AllgayerH., BabicR., GruetznerK.U., TarabichiA., SchildbergF.W., HeissM.M.. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.J Clin Oncol2000; 18: 2201–9.
17.
GarcíaI., VizosoF., MartínA.. Clinical significance of the epidermal growth factor receptor and her2 contents in resectable gastric cancer.Ann Surg Oncol2003; 10: 234–41.
18.
WuJ., AstillM., GagonS., BrysonL.. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.J Clin Lab Anal1995; 9: 151–65.
19.
GarciaI., VizosoF., AndicoecheaA.. C-erbB-2 oncoprotein content in gastric cancer and in adjacent mucosa.Int J Biol Markers2000; 15: 231–4.
BradfordM.. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Anal Biochem1976; 72: 248–54.
22.
CarterP., PrestaL., GormanC.M.. Humanization of an anti-p185HER2 antibody for human cancer therapy.Proc Natl Acad Sci USA1992; 89: 4285–9.
23.
JaehneJ., UrmacherC., ThalerH., Friedlander-KlarH., Cordon-CardoC., MeyerH.. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma.J Cancer Res Clin Oncol1992; 118: 474–9.
24.
WuM.S., ShunC.T., WangH.P.. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection.Gastroenterology1997; 112: 1457–65.
25.
WernerM., BeckerK.F., KellerG., HoflerH.. Gastric adenocarcinoma: pathomorphology and molecular pathology.J Cancer Res Clin Oncol2001; 127: 207–16.
26.
Eppenberger-CastoriS., KuengW., BenzC.. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.J Clin Oncol2001; 19: 645–56.
27.
PressM., HungG., GodolphinW., SlamonD.. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.Cancer Res1994; 54: 2771–7.
28.
PaulettiG., DandekarS., RongH.. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.J Clin Oncol2000; 18: 3651–64.
29.
SlesakB., HarlozinskaA., PorebskaI.. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis.Anticancer Res1998; 18: 2727–32.
30.
WisecarverJ.. HER-2/neu testing comes of age.Am J Clin Pathol1999; 111: 299–301.
